Objective: This systematic review and meta-analysis of randomized controlled trials (RCTs) was performed to summarize the effect of alpha-lipoic acid (ALA) supplementation on glycemic control and lipid profiles among patients with metabolic diseases. Methods: We searched the following databases till October 2017: MEDLINE, EMBASE, Web of Science and Cochrane Central Register of Controlled Trials. The relevant data were extracted and assessed for quality of the studies according to the Cochrane risk of bias tool. Data were pooled using the inverse variance method and expressed as standardized mean difference (SMD) with 95% confidence intervals (95% CI). Heterogeneity between studies was assessed by the Cochran Q statistic and I-squared tests (I 2 ). Twenty-four studies were included in the meta-analyses. Results: The findings of this meta-analysis showed that ALA supplementation among patients with metabolic diseases significantly decreased fasting glucose (SMD -0.54; 95% CI, −0.89, -0.19; P = 0.003), insulin (SMD -1.01; 95% CI, −1.70, −0.31; P = 0.006), homeostasis model assessment of insulin resistance (SMD -0.76; 95% CI, −1.15, -0.36; P b 0.001) and hemoglobin A1c (SMD -1.22; 95% CI, −2.01, -0.44; P = 0.002), triglycerides (SMD -0.58; 95% CI, −1.00, −0.16; P = 0.006), total-(SMD -0.64; 95% CI, −1.01, −0.27; P = 0.001), low density lipoprotein-cholesterol (SMD -0.44; 95% CI, −0.76, −0.11; P = 0.008). We found no detrimental effect of ALA supplementation on high density lipoprotein-cholesterol (HDL-cholesterol) levels (SMD 0.57; 95% CI, −0.14, 1.29; P = 0.11). Conclusions: Overall, the current meta-analysis demonstrated that ALA administration may lead to an improvement in glucose homeostasis parameters and lipid profiles except HDL-cholesterol levels.
Introduction
There are multiple primary and secondary causes of metabolic disturbances related to metabolic syndrome (MetS) including impaired glucose tolerance and hypertriglyceridemia, such as genetics, lifestyle and diet especially obesity and reduced physical activity [1, 2] . Previous studies have reported that MetS is linked to a 2-fold increased risk of cardiovascular disease (CVD) and a 5-fold increased risk of type 2 diabetes mellitus (T2DM) over the next 5 to 10 years [3] . In addition, dyslipidemia [(hypertriglyceridemia, increased levels of total-and low density lipoprotein-cholesterol (LDL-cholesterol) and decreased levels of high density lipoprotein-cholesterol (HDL-cholesterol) is often correlated with insulin resistance, chronic diseases [4, 5] , and increased risk of atherosclerotic events [6] .
Common treatments for managing markers of insulin metabolism and lipid profiles in patients with metabolic diseases include lifestyle changes such as weight loss through an energy-restricted diet together with increased energy expenditure through physical activity, various dietary patterns, and the appropriate use of pharmacological agents to reduction the specific risk factors [7, 8] . To increase compliance and adherence of patients with metabolic diseases to lifestyle changes, complementary therapies including antioxidants supplementation can be useful [9] . Existing evidence has documented the beneficial effects of several antioxidants supplements including phenolic compounds [10] , some vitamins and minerals [9, 11, 12] on complications related to metabolic disorders. Investigations on antidiabetic and antilipidemic characteristic of antioxidants have demonstrated that they can inhibit the expression of cyclooxygenase-2 and P-selectin [13] and stimulate the peroxisome proliferator-activated receptor gamma transduction pathway [14] . Despite reported antidiabetic and antilipidemic characteristics of alpha-lipoic acid (ALA) in some clinical trials [15] [16] [17] , several studies did show no positive effects of ALA on glycemic control and lipid profiles [18, 19] . In addition, two previous meta-analyses studies have reported the beneficial effects of ALA supplementation on weight loss and body mass index, and inflammatory markers [20, 21] . Therefore, ALA supplementation to promote glycemic status and lipid fractions remains controversial. Discrepancies in findings might be the result of differences in study design, characteristics of study populations, dosage of ALA used and duration of the studies.
Despite several randomized controlled trials (RCTs), we are aware of no systematic review and meta-analysis of RCTs about the effect of ALA supplementation on glycemic control and lipid profiles among patients with metabolic diseases. This meta-analysis was performed to summarize the available evidence of RCTs to establish the effect of ALA supplementation on glycemic control and lipid profiles among patients with metabolic diseases.
Methods

Search Strategy and Selection Studies
The design, implementation, analysis, and reporting of this study were conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. We performed a search of Cochrane Library, EMBASE, MEDLINE, and Web of Science databases for relevant RCTs studies published till October 2017. Databases (International Standard Randomized Controlled Trial Number Register and Meta-register for RCTs) were searched for ongoing trials. RCTs retrieved that examined the association between ALA supplementation on glycemic control and lipid profiles using the following MeSH and text keywords: patients ["metabolic disease" OR "MetS" OR "diabetes" OR "T2DM" OR "overweight" OR "obese" OR "gestational diabetes mellitus (GDM)" OR "polycystic ovary syndrome (PCOS)"], intervention ("ALA" OR "α-lipoic acid" AND "supplementation" OR "intake"), and outcomes ["triglycerides (TG) " OR "total-cholesterol (TC)" OR "LDL-cholesterol" OR "LDL-C" OR "HDL-cholesterol" OR "HDL-C" OR "fasting plasma glucose (FPG)" OR "insulin" OR "homeostasis model assessment of insulin resistance (HOMA-IR)" OR "hemoglobin A1c" OR "HbA1c"]. The references list of all known related studies were reviewed to identify additional potential publications that was not captured based on the electronic searches. We applied studies published in the English language without time restrictions for publication. Two independent authors (RT, MA) have selected studies in two-stage process. In the first stage, authors observed the titles and/or abstracted to find trials had potential eligibility. In the second stage, the full texts of related trials were retrieved for detailed evaluation. In the event of a discrepancy, it is resolved by consensus or discussion with a third author (ZA). Studies were selected according to the following criteria: 1) original studies, 2) human RCTs in design, 3) the target population were patients with metabolic diseases, 4) intervention group received of ALA supplements or ALA plus other nutrients, whereas the control group received placebo, and 5) the trials reported mean changes of glycemic control and/or lipid profiles with standard deviation (SD) for the intervention and control groups.
Data Extraction and Quality Assessment
Two authors (VO and MA) independently extracted, as well as two authors assessed (RT and MA) the quality of all relevant studies when there was disagreement, it was resolved by discussion with third author (ZA) or until consensus was reached. The Cochrane Collaboration risk of bias tool used to assess the quality of the included RCTs based on information on the following domains: randomization generation, allocation concealment, blinding of participants and outcome assessment, incomplete outcome data, and selective outcome reporting, and other sources of bias.
Data Analysis
All statistical analyses were performed using STATA version 12.0 (Stata Corp, College Station, TX) and RevMan V.5.3 software (Cochrane Collaboration, Oxford, UK). Heterogeneity between included primary studies was estimated using Cochran's Q test and I-square statistic. Isquare higher than 50% with p b 0.05 represented significant heterogeneity. This study estimated the standardized mean difference (SMD) with 95% confidence interval (CI) by inverse variance method and Cohen statistics. Since the indications could effect on pooled SMD were different between included studies, we used random-effects models for meta-analysis. Subgroup analyses were performed to assess the source of heterogeneity between studies heterogeneity. To explore the contribution of a particular study to the overall mean difference was performed sensitivity analysis. Egger's test and funnel plot were applied to identify the presence of publication bias for the primary outcome measure. The P-value of (2-tailed) b0.05 were considered as statistically significant.
Results
Search Results
Our initial search found 1012 potential citations. After screening articles, 24 papers were found to be eligible for our meta-analysis. The details of step by step study identification and selection were illustrated in Fig. 1 . Fourteen studies were double-blind design, eight studies were randomized, placebo-controlled trial, and two were RCT. Twelve trials examined the effects of ALA on glycemic control and lipid profiles among patients with T2DM [15, 17, 19, [22] [23] [24] [25] [26] [27] [28] [29] [30] and the remaining studies were among other metabolic diseases. Overall, nineteen trials have reported changes in lipid profiles include triglycerides, total-, LDL-and HDL-cholesterol, and twenty studies have reported changes in and glucose metabolism including FPG, insulin, HOMA-IR, and HbA1c. The duration of intervention among studies varied from 2 to 51 weeks. The dosage of ALA supplements used was from 200 to 1800 (mg/day). Six studies were conducted in China [18, 22, 23, [29] [30] [31] , five in Italy [27, [32] [33] [34] [35] , two in Republic of Korea [28, 36] , Iran [15, 37] , and Spain [16, 38] , and one in Brazil [19] , Bosnia and Herzegovina [17] , India [24] , Austria [26] , USA [39] , Thailand [25] , and New Zealand [40] . Table 1 shows the details of the included study characteristics into metaanalysis. The quality of included studies, which was explored using the Cochrane Collaboration risk of bias tool by the judgments of author are presented in Fig. 2 . The findings of risk of bias assessment indicated that three studies were rated at low risk of bias, 19 studies were at unclear risk of bias, and 2 studies were at high risk bias based on the judgments of author. Findings of the subgroup analyses by several suspected variables of the intervention are presented in Table 3 .
Sensitivity analysis was conducted and the results remained consistent with the pooled effect (Fig. 5 ).
Egger's regression tests indicated no significant publication bias for meta-analyses assessing the effects of ALA on FPG (B = −2.25, P = 0.42), insulin (B = −1.33, P = 0.75), HOMA-IR (B = 3.06, P = 0.75), and HbA1c (B = −1.37, P = 0.75).
The Effects of ALA Supplementation on Lipid Profiles
The effects of ALA supplementation on lipid profiles were shown in Fig. 4 . The results showed that ALA supplementation among patients with metabolic diseases significantly decreased triglycerides (SMD -0.58; 95% CI, −1.00, −0.16; P = 0.006), total-(SMD -0.64; 95% CI, −1.01, −0.27; P = 0.001) and LDL-cholesterol (SMD -0.44; 95% CI, −0.76, −0.11; P = 0.008). We found no detrimental effect of ALA Decreased TG, HDL-C, HbA1c, and increased FPG Ansar et al.
[ supplementation on HDL-cholesterol levels (SMD 0.57; 95% CI, −0.14, 1.29; P = 0.11). Table 2 shows all meta-analyses between study population in included trials by pre and post changed in intervention and control groups. Because of existence heterogeneity, we conducted several subgroup analyses by suspected variables including type of diseases, dosage of ALA used, the duration of study, geographic area, and the type of intervention. The effects were different in some of specific groups of studies which the details of subgroup analyses were shown in Table 3 .
Sensitivity analysis was performed and the results for triglycerides, total-, and LDL-cholesterol remained consistent with pooled effect size. But the pooled SMD for HDL-cholesterol found significant difference between the pre-sensitivity pooled SMD (0.57; 95% CI, −0.14, 1.29) and post-sensitivity pooled SMD (0.76; 95% CI, 0.10, 1.42) after excluding Gianturco et al. study (Fig. 5 ).
Egger's regression tests indicated no significant publication bias for meta-analyses assessing the effects of ALA on triglycerides (B = −3.64, P = 0.12), total-(B = −2.17, P = 0.35), HDL-cholesterol (B = 3.03, P = 0.49). Because there was evidence of publication bias on LDL-cholesterol (B = −4.38, P = 0.01), we used non parametric method (Duval and Tweedie) to estimate the results of censored studies. The meta-analysis based on these studies showed that summary effect size on LDL-cholesterol was not significant changed between before included censored studies into meta-analysis (SMD -0.44; 95% CI, −0.76, −0.11) and after (SMD -0.44; 95% CI, −0.76, −0.11).
Discussion
This systematic review and meta-analysis assessed the effect of ALA supplementation on glycemic control and lipid profiles in patients with metabolic diseases. This meta-analysis showed that ALA administration may lead to an improvement in glucose homeostasis parameters and lipid profiles except HDL-cholesterol levels. It must be kept in mind that few metabolic diseases especially diabetes mellitus may lead to neurological complications which its management focuses on glycemic control, multifactorial cardiovascular risk intervention, and pathogenesis-oriented therapy [21] . Existing evidence suggests that ALA increases glutathione levels, prevents lipid peroxidation, enhances the activity of antioxidant enzymes and increases blood flow and glucose uptake diabetic neuropathy [41, 42] . Moreover, ALA may reduce Fig. 3 (continued) . complications related to diabetic neuropathy through modulating deficits of neuropeptides including Neuropeptide Y and substance P in the spinal cord [43] and suppressing the activation of nuclear factor-κB in peripheral nerves [44] . Subjects with metabolic diseases are susceptible to increased risk of CVD, T2DM, and all-cause mortality [3] . The current meta-analysis of RCTs documented that ALA supplementation to populations with metabolic diseases resulted in a significant decrease in fasting glucose, insulin, HOMA-IR and HbA1c. Few studies have evaluated the beneficial effects of antioxidants supplementation on glycemic control in patients with metabolic diseases. In a meta-analysis study, we have previously showed that selenium supplementation to populations with metabolic diseases was useful in improving insulin concentrations and insulin sensitivity, but did not affect fasting glucose and HOMA-IR [9] . In addition, in a systematic study conducted by Cruz et al. [11] , zinc supplementation improved insulin resistance in obese subjects of both sexes. In another meta-analysis study, magnesium supplementation significantly improved glucose parameters in populations with diabetes and also improved insulin-sensitivity parameters in those at high risk of diabetes [45] . Lifestyle can play an important function in treatment of metabolic disorders. However, some clinical trials did not point to the maintenance of usual dietary intake and physical activity levels through the treatment, and most studies did not adjust results for these parameters. Therefore, the effects of lifestyle and other confounding variables are not clear. Several mechanisms have been proposed to mediate the insulin-sensitizing actions of ALA, such as the improvement of glycemic control through the preservation of beta-cell function [46] . In addition, it has been suggested that ALA inhibits the progress of diabetes in diabetes-prone obese rats by decreasing triglycerides accumulation in non-adipose tissues such as muscle, pancreatic beta-cells, and liver [47] . On the other hand, few of these beneficial effects on insulin resistance have been proposed to be mediated by the modulation of adenosine monophosphate-activated protein kinase (AMPK) [47] . Thus, it has been documented that ALA decreases insulin resistance by activating AMPK in skeletal muscle [48] and beta-cells [49] .
Our meta-analysis demonstrated that ALA supplementation to subjects with metabolic diseases was effective in reducing triglycerides, total-and LDL-cholesterol levels, but did not affect HDL-cholesterol levels. Existing evidence from animal models suggests a lipid-lowering response to ALA administration. For example, rats fed a high fat diet with 0.5% ALA shown a decrease in total lipids (21.3%), triglycerides (31.9%), total-(20.1%), LDL-cholesterol (41.1%), and free fatty acids (33%) compared with the control group [50] . In another study, which evaluated the effects of different dosages of ALA (0, 1, 2.5, and 5 g/kg) in Sprague-Dawley rats on lipid profiles demonstrated reductions in triglycerides (68.5%), total cholesterol (25.8%), and non-esterified fatty acids (45%) [51] . In addition, limited evidence from human studies suggests that ALA may have lipid-lowering effects [52] . A short-term (2 weeks) ALA supplementation at a dosage of 600 mg/day to obese populations with impaired glucose tolerance were effective in reducing free fatty acids, triglycerides, total-, LDL-, oxidized LDL-, and VLDLcholesterol concentrations [30] . Masharani et al. [53] demonstrated a significant reduction in triglycerides (28%) and larger, more buoyant LDL-particles in six lean women with PCOS following the supplementation of 600 mg ALA twice daily for 6 weeks. Furthermore, a significant reduction in total cholesterol of 8% and a tendency toward lower LDLand higher HDL-cholesterol following 12 weeks of ALA supplementation at a dosage of 1200 mg/day to overweight/obese schizophrenic patients was observed [54] . Conversely, few human studies have reported no detrimental effect of ALA supplementation on lipid profiles. For example, diabetic end-stage renal disease (ESRD) populations on hemodialysis taking 600 mg/day ALA for 12 weeks exhibited no significant changes in total-cholesterol or oxidized-LDL compared with the control group [28] . In another similar study, Khabbazi et al. [37] did not observe any change in lipid fractions following the supplementation of 600 mg ALA/day for 8 weeks in patients with ESRD on hemodialysis compared with the placebo. Koh et al. [55] demonstrated even after weight loss, no significant change total-, HDL-cholesterol, and triglycerides was reported in obese populations randomized to placebo, 1200 or 1800 mg/day of ALA supplements. Increased AMPK activity following the intake of ALA in peripheral tissues including skeletal muscle has been shown to directly inhibit fatty acid synthesis, while concomitantly elevating in β-oxidation of fatty acids [51, 56] . In addition, some studies document that the expression of the two rate-limiting enzymes in fatty acid synthesis, acetyl-CoA carboxylase and fatty acid synthase, are decreased in response to ALA administration [56, 57] . On the other hand, reductions in lipid profiles following the supplementation of ALA may be secondary to decreases in insulin concentrations and insulin resistance. In addition, previous studies have demonstrated that nutraceuticals play a peculiar role in ameliorating human dyslipidaemia [58, 59 ], which in turn effectively able to decrease the burden of the atherosclerosis process and the progress of CVD [60] . Nutraceuticals may improve lipid profiles through upregulating hepatic LDL receptors, reducing intestinal absorption of cholesterol [61] , blocking carbohydrate digestion and glucose absorption in the gut, decreasing glucose release from liver and activating insulin receptors [62] . Overall, the current meta-analysis demonstrated that ALA administration may lead to an improvement in glucose homeostasis parameters and lipid profiles except HDL-cholesterol levels. The findings of this meta-analysis may have a high impact in the field of nutraceuticals and therapy for metabolic diseases. Additional prospective studies investigating the effect of ALA supplementation on glucose homeostasis parameters and lipid profiles in MetS are necessary.
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